Share
Market Research Report

TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Segmentation
  • By Drug TypeTafamidis (Vyndaqel) · Patisiran (ONPATTRO) · Inotersen (TEGSEDI) · and Others
  • By Disease TypeHereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed Type) and Wild Type Amyloidosis
  • By Distribution ChannelHospital Pharmacies · Specialty Pharmacies · Retail Pharmacies · and Online Pharmacies
  • By GeographyNorth America · Latin America · Europe · Asia Pacific · Middle East & Africa
  • Published In15 Jun 2026
  • Report CodeCMI687
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026 - 2033

Market Segmentation

  • By Drug Type (Revenue, USD Bn, 2021-2033)

    • Tafamidis (Vyndaqel)
    • Patisiran (ONPATTRO)
    • Inotersen (TEGSEDI)
    • Others

  • By Disease Type (Revenue, USD Bn, 2021-2033)

    • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
    • Wild Type Amyloidosis

  • By Distribution Channel (Revenue, USD Bn, 2021-2033)

    • Hospital Pharmacies
    • Specialty Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

  • By Region (Revenue, USD Bn, 2021-2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Central Africa
      • North Africa